SCHEMBL4135628

SCHEMBL4135628

CCCCCC(C(C)=O)C(=O)OCC

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.45
TDP1 Q9NUW8 4/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ZDHHC7 Q9NXF8 1/20 0.43
L3MBTL1 Q9Y468 3/20 0.40
MAPT P10636 3/20 0.40
MAPK1 P28482 2/20 0.40
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40
GPR84 Q9NQS5 3/20 0.39
FFAR1 O14842 1/20 0.39
CA1 P00915 1/20 0.39
ALDH1A1 P00352 3/20 0.39
LMNA P02545 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TSHR P16473 1/20 0.39
CPB2 Q96IY4 1/20 0.39
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1393537 0.98 FAAH (0.47) FAAHTDP1MEN1KMT2AZDHHC7
SCHEMBL1393272 0.98 FAAH (0.47) FAAHTDP1MEN1KMT2AZDHHC7
SCHEMBL11358682 0.98 FAAH (0.47) FAAHTDP1MEN1KMT2AZDHHC7
SCHEMBL4904972 0.98 FAAH (0.47) FAAHTDP1MEN1KMT2AZDHHC7
SCHEMBL6309982 0.98 FAAH (0.47) FAAHTDP1MEN1KMT2AZDHHC7
SCHEMBL873537 0.98 FAAH (0.47) FAAHTDP1MEN1KMT2AZDHHC7
SCHEMBL486944 0.98 FAAH (0.47) FAAHTDP1MEN1KMT2AZDHHC7
SCHEMBL28280400 0.96 FAAH (0.46) FAAHTDP1MEN1KMT2AZDHHC7
SCHEMBL650590 0.94 TDP1 (0.45) FAAHTDP1MEN1KMT2AL3MBTL1
SCHEMBL482827 0.92 TDP1 (0.46) FAAHTDP1MEN1KMT2AZDHHC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1151120-A1 INDUCIBLE EXPRESSION SYSTEM FOR USE IN PLANTS Syngenta Limited (GB) 2001-11-07 EP claimed
WO-2000044917-A1 INDUCIBLE EXPRESSION SYSTEM FOR USE IN PLANTS SYNGENTA LIMITED (GB) 2000-08-03 WO claimed
EP-0180745-A1 Acylacetate and amidine intermediates for pyrimidone compounds, and their preparation YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1986-05-14 EP claimed
US-20230210808-A1 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS CYMABAY THERAPEUTICS, INC. 2023-07-06 US disclosed
EP-2876671-B1 COMPOSITION FOR FORMING PASSIVATION LAYER, SEMICONDUCTOR SUBSTRATE HAVING PASSIVATION LAYER, METHOD OF PRODUCING SEMICONDUCTOR SUBSTRATE HAVING PASSIVATION LAYER, PHOTOVOLTAIC CELL ELEMENT, AND PHOTOVOLTAIC CELL HITACHI CHEMICAL CO LTD (JP) 2017-11-22 EP disclosed
US-20170304254-A1 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS JANSSEN PHARMACEUTICA NV (DE) 2017-10-26 US disclosed
US-9724322-B2 4-(phenoxyalkyl)thio)-phenoxyacetic acids and analogs JANSSEN PHARMACEUTICA N.V. (BE) 2017-08-08 US disclosed
US-9714262-B2 Composition for forming passivation layer, semiconductor substrate having passivation layer, method of producing semiconductor substrate having passivation layer, photovoltaic cell element, method of producing photovoltaic cell element and photovoltaic cell HITACHI CHEMICAL COMPANY, LTD. (JP) 2017-07-25 US disclosed
US-20160211389-A1 COMPOSITION FOR FORMING PASSIVATION LAYER, SEMICONDUCTOR SUBSTRATE HAVING PASSIVATION LAYER, METHOD OF PRODUCING SEMICONDUCTOR SUBSTRATE HAVING PASSIVATION LAYER, PHOTOV OLTAIC CELL ELEMENT, METHOD OF PRODUCING PHOTOVOLTAIC CELL ELEMENT, AND PHOTOVOLTAIC CELL HITACHI CHEMICAL COMPANY, LTD. (JP) 2016-07-21 US disclosed
US-20160199342-A1 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS CYMABAY THERAPEUTICS, INC. 2016-07-14 US disclosed
US-20150303317-A1 SEMICONDUCTOR SUBSTRATE PROVIDED WITH PASSIVATION FILM AND PRODUCTION METHOD, AND PHOTOVOLTAIC CELL ELEMENT AND PRODUCTION METHOD THEREFOR HITACHI CHEMICAL COMPANY, LTD. (JP) 2015-10-22 US disclosed
EP-0937703-A1 METHOD FOR PURIFYING PYRUVIC ACID COMPOUNDS SUMITOMO CHEMICAL COMPANY LIMITED (JP) 1999-08-25 EP disclosed
WO-1996006061-A2 LATERALLY SUBSTITUTED CHLOROARENES, THEIR MANUFACTURE AND MIXTURES CONTAINING THEM WOJSKOWA AKADEMIA TECHNICZNA (PL) 1996-02-29 WO disclosed
US-4584384-A HISTAMINE H2-ANTAGONISTS SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1986-04-22 US disclosed
US-4482563-A HISTAMINE H2-ANTAGONIST SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1984-11-13 US disclosed
US-4407808-A 2-Heterocyclic alkylamino-3-nitropyrroles SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1983-10-04 US disclosed
EP-0005985-B1 3-NITRO PYRROLE COMPOUNDS, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1983-04-27 EP disclosed
US-4331668-A ANTIHISTAMINE, ANTAGONIST SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1982-05-25 US disclosed
US-4238494-A HISTAMINE H2-RECEPTOR ANTAGONIST SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1980-12-09 US disclosed
EP-0005985-A1 3-Nitro pyrrole compounds, processes for preparing them and pharmaceutical compositions containing them SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1979-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210808-A1 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS PPARA, PPARG, PPARD FAAH 1207/4885TDP1 3631/4885MEN1 4877/4885
US-20170304254-A1 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS PPARA, PPARG, PPARD FAAH 1207/4885TDP1 3631/4885MEN1 4877/4885
US-20160199342-A1 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS PPARA, PPARG, PPARD FAAH 1207/4885TDP1 3631/4885MEN1 4877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.